Drug response prediction in high-risk multiple myeloma

TY - JOUR

T1 - Drug response prediction in high-risk multiple myeloma

AU - Vangsted, A. J.

AU - Helm-Petersen, S.

AU - Cowland, J. B.

AU - Jensen, P. B.

AU - Gimsing, P.

AU - Barlogie, B.

AU - Knudsen, S.

PY - 2018

Y1 - 2018

N2 - A Drug Response Prediction (DRP) score was developed based on gene expression profiling (GEP) from cell lines and tumor samples. Twenty percent of high-risk patients by GEP70 treated in Total Therapy 2 and 3A have a progression-free survival (PFS) of more than 10 years. We used available GEP data from high-risk patients by GEP70 at diagnosis from Total Therapy 2 and 3A to predict the response by the DRP score of drugs used in the treatment of myeloma patients. The DRP score stratified patients further. High-risk myeloma with a predicted sensitivity to melphalan by the DRP score had a prolonged PFS, HR = 2.4 (1.2–4.9, P = 0.014) and those with predicted sensitivity to bortezomib had a HR 5.7 (1.2–27, P = 0.027). In case of predicted sensitivity to bortezomib, a better response to treatment was found (P = 0.022). This method may provide us with a tool for identifying candidates for effective personalized medicine and spare potential non-responders from suffering toxicity.

AB - A Drug Response Prediction (DRP) score was developed based on gene expression profiling (GEP) from cell lines and tumor samples. Twenty percent of high-risk patients by GEP70 treated in Total Therapy 2 and 3A have a progression-free survival (PFS) of more than 10 years. We used available GEP data from high-risk patients by GEP70 at diagnosis from Total Therapy 2 and 3A to predict the response by the DRP score of drugs used in the treatment of myeloma patients. The DRP score stratified patients further. High-risk myeloma with a predicted sensitivity to melphalan by the DRP score had a prolonged PFS, HR = 2.4 (1.2–4.9, P = 0.014) and those with predicted sensitivity to bortezomib had a HR 5.7 (1.2–27, P = 0.027). In case of predicted sensitivity to bortezomib, a better response to treatment was found (P = 0.022). This method may provide us with a tool for identifying candidates for effective personalized medicine and spare potential non-responders from suffering toxicity.

KW - Drug response prediction

KW - High-risk

KW - Multiple myeloma

U2 - 10.1016/j.gene.2017.10.071

DO - 10.1016/j.gene.2017.10.071

M3 - Journal article

C2 - 29122646

AN - SCOPUS:85034446843

SN - 0378-1119

VL - 644

SP - 80

EP - 86

JO - Gene

JF - Gene

ER -